Pathogenesis of pediatric multiple sclerosis

David Vargas-Lowy1, Tanuja Chitnis

  • 1Center for Neurological Diseases, Department of Neurology, Brigham and Women's Hospital, Boston, MA 02114, USA.

Journal of Child Neurology
|September 7, 2012
PubMed

Insights

Pediatric multiple sclerosis (MS) research is advancing, offering insights into disease initiation, biomarkers, and treatment. Understanding childhood MS pathogenesis may reveal general risk factors and differences from adult-onset MS.

Area of Science:

  • Neurology
  • Immunology
  • Pediatrics

Background:

  • Multiple sclerosis (MS) onset in children affects 3-5% of patients.
  • Knowledge of pediatric MS pathobiology is limited but expanding.

Purpose of the Study:

  • To review current knowledge on pediatric MS pathogenesis.
  • To address key questions regarding disease initiation, biomarkers, pathogenesis differences from adult MS, treatment optimization, and environmental risk factors.

Main Methods:

  • Literature review of pediatric multiple sclerosis.
  • Analysis of current research on pathogenesis and clinical aspects.

Main Results:

  • Discussion of factors influencing pediatric MS initiation and propagation.
  • Exploration of potential biomarkers for disease course.
  • Comparison of pediatric MS pathogenesis with adult-onset MS.
  • Consideration of treatment strategies for pediatric demyelinating diseases.
  • Investigation of insights into general MS environmental risk factors.

Conclusions:

  • Further research into pediatric MS is crucial for understanding MS etiology and improving patient outcomes.
  • Pediatric MS may offer unique insights into the broader spectrum of multiple sclerosis.

Related Concept Videos

Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
Encephalitis ll: Pathophysiology01:26

Encephalitis ll: Pathophysiology

Encephalitis is inflammation of the brain parenchyma caused by direct viral invasion or immune-mediated mechanisms triggered by infections or tumors. Both processes lead to neuronal injury, disrupted neurotransmission, and diverse neurological symptoms, often with overlapping clinical and pathological features.Autoimmune EncephalitisIn autoimmune encephalitis, antibodies target neuronal antigens on cell surfaces, synapses, or within neurons. A key example is anti-NMDAR encephalitis, which can...
Bacterial Meningitis II: Pathophysiology01:26

Bacterial Meningitis II: Pathophysiology

Bacterial meningitis typically begins when pathogens such as Neisseria meningitidis and Streptococcus pneumoniae colonize the nasopharynx and invade the bloodstream. This process is facilitated by bacterial virulence factors, such as polysaccharide capsules, which resist phagocytosis and complement-mediated killing. Less commonly, bacteria reach the central nervous system via contiguous spread from infections like otitis media or sinusitis, through congenital or acquired dural defects, or...
Parkinson Disease ll: Pathophysiology01:24

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
Myasthenia Gravis ll: Pathophysiology01:22

Myasthenia Gravis ll: Pathophysiology

The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...
Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders01:27

Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders

Schizophrenia is a neurodevelopmental disorder whose origins are rooted in complex genetic components. Despite our burgeoning understanding, the pathophysiology of this disorder remains incompletely deciphered.
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within the...